Madrigal Pharmaceuticals will announce Q2 2025 financial results on August 5, followed by a live webcast.
Quiver AI Summary
Madrigal Pharmaceuticals, Inc. announced that it will release its second-quarter 2025 financial results on August 5, 2025, before U.S. markets open. Following this announcement, company management will hold a live webcast at 8 a.m. Eastern Time to discuss the financial and operational outcomes, accessible through the Investor Relations section of their website. Participants are encouraged to register in advance. Madrigal focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its drug Rezdiffra being the first FDA-approved therapy for this condition. The company is also conducting a Phase 3 trial for Rezdiffra aimed at treating compensated MASH cirrhosis. Further information can be found on their website.
Potential Positives
- Madrigal Pharmaceuticals plans to release its second-quarter 2025 financial results, indicating transparency and communication with investors.
- The company will host a live webcast to discuss its financial and operating results, facilitating direct engagement with shareholders.
- Madrigal’s medication, Rezdiffra, is highlighted as the first and only FDA-approved treatment for MASH with moderate to advanced fibrosis, showcasing the company's innovative product offering in a high unmet medical need area.
- An ongoing Phase 3 trial for Rezdiffra in compensated MASH cirrhosis suggests ongoing commitment to research and development, potentially leading to future product approvals and market expansion.
Potential Negatives
- None
FAQ
When will Madrigal Pharmaceuticals release its Q2 2025 financial results?
Madrigal Pharmaceuticals will release its second-quarter 2025 financial results on Wednesday, August 5, 2025.
What time is the Madrigal Pharmaceuticals Q2 webcast?
The live webcast will take place at 8 a.m. Eastern Time on August 5, 2025.
How can I access the Madrigal Pharmaceuticals webcast?
The webcast can be accessed in the Investor Relations section of the Madrigal Pharmaceuticals website.
What is Rezdiffra from Madrigal Pharmaceuticals?
Rezdiffra (resmetirom) is the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis.
Where can I find more information about Madrigal Pharmaceuticals?
More information about Madrigal Pharmaceuticals can be found on their official website, www.madrigalpharma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDGL Insider Trading Activity
$MDGL insiders have traded $MDGL stock on the open market 61 times in the past 6 months. Of those trades, 0 have been purchases and 61 have been sales.
Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:
- REBECCA TAUB has made 0 purchases and 11 sales selling 30,749 shares for an estimated $10,845,338.
- PAUL A FRIEDMAN has made 0 purchases and 10 sales selling 30,276 shares for an estimated $10,688,888.
- ROBERT E. WALTERMIRE (Senior VP, Chief Pharma Dev.) has made 0 purchases and 12 sales selling 15,443 shares for an estimated $5,270,121.
- FRED B CRAVES has made 0 purchases and 13 sales selling 15,470 shares for an estimated $5,082,479.
- MARDI DIER (SVP and CFO) has made 0 purchases and 3 sales selling 2,219 shares for an estimated $720,592.
- CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 10 sales selling 2,181 shares for an estimated $714,167.
- WILLIAM JOHN SIBOLD (President and CEO) sold 1,584 shares for an estimated $531,020
- SHANNON T KELLEY (General Counsel) sold 415 shares for an estimated $139,025
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDGL Hedge Fund Activity
We have seen 163 institutional investors add shares of $MDGL stock to their portfolio, and 134 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOLOCENE ADVISORS, LP added 390,545 shares (+inf%) to their portfolio in Q1 2025, for an estimated $129,360,220
- FMR LLC removed 215,751 shares (-24.9%) from their portfolio in Q1 2025, for an estimated $71,463,203
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 171,649 shares (+860.0%) to their portfolio in Q1 2025, for an estimated $56,855,298
- MORGAN STANLEY added 166,347 shares (+76.1%) to their portfolio in Q1 2025, for an estimated $55,099,116
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 126,320 shares (+773.9%) to their portfolio in Q1 2025, for an estimated $41,840,973
- SIREN, L.L.C. removed 125,942 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $41,715,768
- HOOD RIVER CAPITAL MANAGEMENT LLC added 116,155 shares (+90.9%) to their portfolio in Q1 2025, for an estimated $38,474,020
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDGL Analyst Ratings
Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/02/2025
- B. Riley Securities issued a "Buy" rating on 05/02/2025
- Canaccord Genuity issued a "Buy" rating on 05/02/2025
- JMP Securities issued a "Market Outperform" rating on 04/24/2025
- Citigroup issued a "Buy" rating on 02/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 02/27/2025
To track analyst ratings and price targets for $MDGL, check out Quiver Quantitative's $MDGL forecast page.
$MDGL Price Targets
Multiple analysts have issued price targets for $MDGL recently. We have seen 6 analysts offer price targets for $MDGL in the last 6 months, with a median target of $450.5.
Here are some recent targets:
- Eliana Merle from UBS set a target price of $458.0 on 05/02/2025
- Mayank Mamtani from B. Riley Securities set a target price of $460.0 on 05/02/2025
- Edward Nash from Canaccord Genuity set a target price of $420.0 on 05/02/2025
- Jonathan Wolleben from JMP Securities set a target price of $443.0 on 04/24/2025
- David Lebovitz from Citigroup set a target price of $469.0 on 02/27/2025
- Ed Arce from HC Wainwright & Co. set a target price of $405.0 on 02/27/2025
Full Release
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its second-quarter 2025 financial results on Wednesday, Aug. 5, 2025, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m.
Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit
www.madrigalpharma.com
.
Investor Contact
Tina Ventura,
[email protected]
Media Contact
Christopher Frates,
[email protected]
